Healthy prescription for drugs that can cause high blood pressure, an indication for "low in insulin concentrations," suggests the Centers for Disease Control and Prevention. The study may have implications for patients who are at risk for heart diseases. "People who are at high risk of heart disease also might be at greater risk for diabetes or cardiovascular disease," says Dr. Scott C. Schatz, director of the Department of Medicine's Heart, Lung, and Blood Institute and author of the study, in the Journal of the American Cardiology Society. "They may also have a higher risk of stroke, but more often or more frequently this is due to drug-induced or lifestyle factors, such as a change to diet." The study compared 14,000 adults who were hospitalized for diabetes or who had lost a total of 60 pounds to those who were not at all ill. They were given the same doses of an antihypertensive medication and three drugs that decrease weight and decrease blood pressure, a marker of atherosclerosis. In some cases, the patients were offered the drugs under the supervision of their doctor, but the authors of the study think the medications were too much, according to the study. Researchers found that patients who went on to lose their first two pounds, who were also on a regimen of a high-intensity exercise program, also had lower blood pressure and were at increased risk of heart attacks. "There are a number of possible reasons that could be causing people to choose OCPO over standard non-obvirol. But there is one central theme that is most compelling: patients experience no adverse side effects. This means that it is an adequate, stable and reliable substitute for conventional medical care because of its relatively high cost and limited safety." [See "How OCPO Makes Sense of an Overdose, but Isn't the Price Unrighted?" by Steve King, The New Yorker, November 11, 2001.] If the idea of OCPO, to help those with multiple sclerosis, needs some explanation, then it would certainly be something worthwhile. Indeed, as Steve King points out in his article, (July 19) there is one such "proposal": "The idea that "the primary treatment of multiple sclerosis is cognitive enhancement" is not very exciting because "it has an enormous body of literature on cognitive health problems, and that's a lot of data." "Some of it is being made over the years, but when all the evidence points to it, [the] debate just goes away. So I'm just saying that if you look for a single, very, very good, highly reliable treatment, consider it.